The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1299
November 17, 2008
View Complete Issue         Table of Contents 2019 
Bendamustine (Treanda) for CLL and NHL
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Bendamustine (Treanda) for CLL and NHL
November 17, 2008 (Issue: 1299)
Bendamustine HCl (Treanda - Cephalon), an unusual DNA-alkylating agent that has been used in Europe for many years to treat lymphoma, has now been approved by the FDA for treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Bendamustine (Treanda) for CLL and NHL
Article code: 1299c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.